ClinicalTrials.gg
RecruitingNCT05519332Updated Apr 4, 2025

Percutaneous Vertebral-disc Plasty for Thoracolumbar Very Severe Osteoporotic Vertebral Compression Fractures

An interventional study of percutaneous vertebral-disc plasty in Osteoporotic Fracture of Vertebra, sponsored by Jiawei Jiang. Recruiting at 1 site in China. Open to participants aged 58 Years to 84 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Jiawei Jiang · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 5 months after the study started (first participant enrolled Mar 2020, registered Aug 2022).
  • Started Mar 2020; still recruiting 6 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
58 Years to 84 Years
Sex
All
01

Study summary

Purpose: To compare the clinical outcomes and radiological parameters of patients undergoing percutaneous vertebroplasty (PVP) versus those undergoing percutaneous vertebral-disc plasty (PVDP) for back pain, segmental instability, and kyphosis due to thoracolumbar very severe osteoporotic vertebral compression fractures (vsOVCFs).

This prospective study included elderly patients with thoracolumbar vsOVCFs. All the patients were randomly allocated into the PVP group (who underwent conventional PVP) and the PVDP group (who underwent PVP combined percutaneous cement discoplasty). The visual analogue scale (VAS), Oswestry Disability Index (ODI), local kyphosis angle, and disc height were recorded preoperatively and postoperatively.

Read the detailed description

Patients diagnosed with thoracolumbar vsOVCFs in hospital and undergoing minimally invasive treatment from November 2019 to March 2021 were enrolled for the study. They were randomly allocated into two groups (based on random numbers generated by www. randomizer.org), namely PVP group and PVDP group.

Operative technique:In PVDP group, PVP and PCD both used a unilateral transpedicular approach into the vertebrae and disc. . Under general anesthesia, the patient was turned over to a prone position, and the deformity is reduced with a slight closed manipulative. Firstly, under fluoroscopic O-arm guidance, the puncture site was localized into the junction made by the transverse process and the superior articular process and entered the target area according to the puncture angle and depth measured before the operation. Secondly, the other puncture cannula was inserted into the intervertebral disc space adjacent to the ruptured endplate through the transpedicular access, and the target area was the middle of the intervertebral space. Thin-cut CT images were obtained intraoperatively by the O-arm fluoroscopy to confirm puncture needle placement location. Third, the bone cement was injected into the vertebrae and the intervertebral disc space, meanwhile, the cannula was also needed to move back to the vertebrae, and the bone cement in the vertebrae could connect the intervertebral disc space and the vertebrae to form a whole. Finally, the PVP group and the adjacent vertebrae performed by prophylactic vertebroplasty used bilateral pedicle puncture, under the guidance of the O-arm, two puncture needles were percutaneously inserted into the vertebrae, reaching about the middle of the vertebrae. Then, cement was slowly injected into the vertebral body, once cement leakage into the spinal canal or veins was detected, the injection was stopped.

The investigators measured radiological parameters including the local kyphotic angle (LKA), disc height anterior (DHA), and disc height posterior (DHP) from lateral plain radiographs preoperatively and at 1 day and final follow-up after surgery. The visual analog score (VAS) was used to assess the preoperative and postoperative back pain relief. The Oswestry Disability Index (ODI) was used to assess the quality of life and was recorded preoperatively, postoperatively, and final follow-up.

02

Conditions studied

  • Osteoporotic Fracture of Vertebra

Browse trials for

Keywords

  • percutaneous vertebroplasty
  • percutaneous cement discoplasty
03

In context

Osteoporotic Fractures

87 studies on the registry are indexed under Osteoporotic Fractures; 22 are open to participants now.

This study's planned enrollment of 100 is below the median of 120 across 49 interventional studies indexed under Osteoporotic Fractures.

Browse Osteoporotic Fractures studies →

Lead sponsor

Jiawei Jiang is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
58 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • bone mineral density T scores \<-2.5;
  • compression of the vertebral anterior column greater than two-thirds of their original height;
  • Kyphosis with LKA greater than 20°;
  • the accordion phenomenon: the different angles of a supine CT scan and a lateral standing X-ray measurement;
  • upper or lower vertebral endplate fracture;
  • the involved vertebral body was intact;
  • Elderly patients with a history of major illness (such as cardiovascular disease, cancer or active ) and were intolerant of the traditional open surgery.

Exclusion criteria

Exclusion Criteria:

  • Pathological vertebral fractures caused by spinal tumors, spinal tuberculosis, and spinal infection and so on;
  • Patients with symptoms of nerve roots or spinal cord compression;
  • Patients with a previous history of spinal fusion;
  • A history of abnormal bleeding or coagulation disorder dysfunction.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    PVDP group

    Patients underwent percutaneous vertebral-disc plasty

    Procedure: percutaneous vertebral-disc plasty

  • No intervention
    PVP group

    Patients underwent conventional percutaneous vertebroplasty

Interventions

  • Procedurepercutaneous vertebral-disc plasty

    percutaneous vertebroplasty combined percutaneous cement discoplasty

06

What researchers measure

Primary outcomes

  1. Change from Baseline visual analogue scale

    Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0 to 100. A higher score indicates greater pain intensity. Based on the distribution of pain Visual Analogue Scale scores in post-surgical patients who described their postoperative pain intensity as none, mild, moderate, or severe, the following cut points on the pain Visual Analogue Scale have been recommended: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).

    Time frame: One day before operation, one day after operation and 1year.

  2. Change from Baseline Oswestry Disability Index

    The ODI assesses ten aspects of daily functions viz. pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life and travelling. An ODI of 0-20% indicates minimal disability; the patients can cope with most living activities and usually no treatment is indicated, apart from advice on lifting, sitting and exercise. An ODI of 21-40% indicates moderate disability; the patients experience more pain and difficulty with sitting, lifting and standing; travel and social life are more difficult and they may be disabled from work; personal care, sexual activity and sleeping are not grossly affected. An ODI of 41-60% indicates severe disability; pain remains the main problem in this group of patients; the activities of daily living are affected. Patients with an ODI of 61-80% are severely crippled in function with back pain impinging on all aspects of the patient's life. Finally, an ODI of 81-100% indicates that the patients are bed-bound.

    Time frame: One day before operation, one day after operation and 1year.

  3. Change from Baseline the local kyphotic angle

    The local kyphotic angle (LKA) was calculated by a measurement called Cobb's method, which measured the angle between the superior endplate of the upper vertebrae and the inferior endplate of the lower vertebrae. Use this to assess the degree of local kyphosis of the spine.

    Time frame: One day before operation, one day after operation and 1year.

Secondary outcomes

  1. Change from Baseline the disc height anterior

    Disc height anterior(DHA) was measured from the anterior points of the disc on lateral plain radiographs. It is used to assess the degree of height loss at the anterior border of the intervertebral space.

    Time frame: One day before operation, one day after operation and 1year.

  2. Change from Baseline the disc height posterior

    Disc height posterior (DHP) was measured from the posterior points of the disc on lateral plain radiographs. It is used to assess the degree of height loss at the posterior border of the intervertebral space.

    Time frame: One day before operation, one day after operation and 1year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Jul 2025, 64 months after the start.

Of 22 interventional studies with no phase under Osteoporotic Fractures, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's planned 64 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Aug 29, 2022
StartActual
Mar 1, 2020
Primary completionEst.
Jul 2025
CompletionEst.
Dec 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05519332
Lead sponsor
Jiawei Jiang
Responsible party
Jiawei Jiang (resident physician, Affiliated 2 Hospital of Nantong University) — Sponsor-investigator
First posted
Aug 29, 2022
Start date
Mar 1, 2020
Primary completion
Jul 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 4, 2025

Study contacts

Jiawei Jiang, Dr
Contact
18862802782@163.com
18862802782
Guanhua Xu, Dr
principal investigator · Affiliated 2 Hospital of Nantong University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion